AU4597596A - Creation of Inventions and Patents with Artificial Intelligence

AU4597596A – Prevention of protein aggregation
– Google Patents

AU4597596A – Prevention of protein aggregation
– Google Patents
Prevention of protein aggregation

Info

Publication number
AU4597596A

AU4597596A
AU45975/96A
AU4597596A
AU4597596A
AU 4597596 A
AU4597596 A
AU 4597596A
AU 45975/96 A
AU45975/96 A
AU 45975/96A
AU 4597596 A
AU4597596 A
AU 4597596A
AU 4597596 A
AU4597596 A
AU 4597596A
Authority
AU
Australia
Prior art keywords
prevention
protein aggregation
aggregation
protein
Prior art date
1994-12-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Application number
AU45975/96A
Inventor
Beka Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ramot at Tel Aviv University Ltd

Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1994-12-16
Filing date
1995-12-13
Publication date
1996-07-03
Family has litigation

First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=23411044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU4597596(A)
“Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-12-13
Application filed by Ramot at Tel Aviv University Ltd
filed
Critical
Ramot at Tel Aviv University Ltd

1996-07-03
Publication of AU4597596A
publication
Critical
patent/AU4597596A/en

Status
Abandoned
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

G—PHYSICS

G01—MEASURING; TESTING

G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES

G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00

G01N33/48—Biological material, e.g. blood, urine; Haemocytometers

G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

AU45975/96A
1994-12-16
1995-12-13
Prevention of protein aggregation

Abandoned

AU4597596A
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

US358786

1989-05-26

US08/358,786

US5688651A
(en)

1994-12-16
1994-12-16
Prevention of protein aggregation

PCT/US1995/016092

WO1996018900A1
(en)

1994-12-16
1995-12-13
Prevention of protein aggregation

Publications (1)

Publication Number
Publication Date

AU4597596A
true

AU4597596A
(en)

1996-07-03

Family
ID=23411044
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU45975/96A
Abandoned

AU4597596A
(en)

1994-12-16
1995-12-13
Prevention of protein aggregation

Country Status (4)

Country
Link

US
(1)

US5688651A
(en)

AU
(1)

AU4597596A
(en)

IL
(1)

IL116416A
(en)

WO
(1)

WO1996018900A1
(en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US6717031B2
(en)

1995-06-07
2004-04-06
Kate Dora Games
Method for selecting a transgenic mouse model of alzheimer’s disease

AU1072897A
(en)

1995-12-12
1997-07-03
Karolinska Innovations Ab
Peptide binding the klvff-sequence of amyloid beta

US6451541B1
(en)

1996-05-14
2002-09-17
Ernst-Ludwig Winnacker
Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc

JP2001514661A
(en)

1997-03-11
2001-09-11
ザジェネラルホスピタルコーポレイション

Identification of drugs for use in treating Alzheimer’s disease

US7045531B1
(en)

1997-03-11
2006-05-16
The General Hospital Corporation
Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator

SI0994728T1
(en)

1997-04-09
2009-02-28
Intellect Neurosciences Inc
Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof

US8173127B2
(en)

1997-04-09
2012-05-08
Intellect Neurosciences, Inc.
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof

US6703015B1
(en)

1999-09-03
2004-03-09
Ramot At Tel-Aviv University Ltd.
Filamentous bacteriophage displaying an β-amyloid epitope

US7588766B1
(en)

2000-05-26
2009-09-15
Elan Pharma International Limited
Treatment of amyloidogenic disease

US7964192B1
(en)

1997-12-02
2011-06-21
Janssen Alzheimer Immunotherapy
Prevention and treatment of amyloidgenic disease

TWI239847B
(en)

1997-12-02
2005-09-21
Elan Pharm Inc
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

US6761888B1
(en)

2000-05-26
2004-07-13
Neuralab Limited
Passive immunization treatment of Alzheimer’s disease

US6923964B1
(en)

1997-12-02
2005-08-02
Neuralab Limited
Active immunization of AScr for prion disorders

US20080050367A1
(en)

1998-04-07
2008-02-28
Guriq Basi
Humanized antibodies that recognize beta amyloid peptide

US6787523B1
(en)

1997-12-02
2004-09-07
Neuralab Limited
Prevention and treatment of amyloidogenic disease

US6710226B1
(en)

1997-12-02
2004-03-23
Neuralab Limited
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer’s disease characteristics

US7790856B2
(en)

1998-04-07
2010-09-07
Janssen Alzheimer Immunotherapy
Humanized antibodies that recognize beta amyloid peptide

US6913745B1
(en)

1997-12-02
2005-07-05
Neuralab Limited
Passive immunization of Alzheimer’s disease

US6743427B1
(en)

1997-12-02
2004-06-01
Neuralab Limited
Prevention and treatment of amyloidogenic disease

US6750324B1
(en)

1997-12-02
2004-06-15
Neuralab Limited
Humanized and chimeric N-terminal amyloid beta-antibodies

US7179892B2
(en)

2000-12-06
2007-02-20
Neuralab Limited
Humanized antibodies that recognize beta amyloid peptide

US20020025944A1
(en)

2000-04-28
2002-02-28
Bush Ashley I.
Use of clioquinol for the therapy of Alzheimer’s disease

US6638711B1
(en)

1999-04-29
2003-10-28
The General Hospital Corporation
Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation

US6323218B1
(en)

1998-03-11
2001-11-27
The General Hospital Corporation
Agents for use in the treatment of Alzheimer’s disease

US20050112543A1
(en)

1998-03-11
2005-05-26
The General Hospital Corporation
Method of screening for drugs useful in treating Alzheimer’s disease

US20050059802A1
(en)

1998-04-07
2005-03-17
Neuralab Ltd
Prevention and treatment of amyloidogenic disease

US20030147882A1
(en)

1998-05-21
2003-08-07
Alan Solomon
Methods for amyloid removal using anti-amyloid antibodies

US20010027182A1
(en)

1998-05-29
2001-10-04
Huda Y. Zoghbi
Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfilind in sca1

US7060670B1
(en)

1999-05-05
2006-06-13
Neurochem (International) Limited
Stereoselective antifibrillogenic peptides and peptidomimetics thereof

US6787637B1
(en)

1999-05-28
2004-09-07
Neuralab Limited
N-Terminal amyloid-β antibodies

CA2375104C
(en)

1999-06-01
2013-12-24
Neuralab Limited
Prevention and treatment of amyloidogenic disease

US6919075B1
(en)

1999-09-03
2005-07-19
Ramot At Tel Aviv University Ltd.
Bacteriophage displaying aβ epitopes and method of use

US20040013647A1
(en)

1999-09-03
2004-01-22
Ramot At Tel-Aviv University Ltd.
Methods and compositions for treating a plaque-forming disease

US6420122B1
(en)

1999-09-27
2002-07-16
Massachusetts Institute Of Technology
Methods of screening for agents that inhibit aggregation of polypeptides

US20070135337A2
(en)

1999-11-29
2007-06-14
Neurochem (International) Limited
Vaccine for the Prevention and Treatment of Alzheimer’s and Amyloid Related Diseases

US20020094335A1
(en)

1999-11-29
2002-07-18
Robert Chalifour
Vaccine for the prevention and treatment of alzheimer’s and amyloid related diseases

KR100767146B1
(en)

2000-02-24
2007-10-15
워싱톤 유니버시티
Humanized Antibodies That Sequester Amyloid Beta Peptide

CN1321646A
(en)

2000-04-29
2001-11-14
上海博德基因开发有限公司
Novel polypeptide-human inclusion analogous protein 9 and polynucleotide for coding this polypeptide

IL152625A0
(en)

2000-05-22
2003-06-24
Univ New York
SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID beta FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID beta AND AMYLOID DEPOSITS

ES2389811T3
(en)

2000-06-28
2012-10-31
Prana Biotechnology Limited

Amyloid beta oligomers for use in the treatment, relief or prevention of Alzheimer’s disease

US6716589B2
(en)

2000-11-20
2004-04-06
Alphabeta Ab
Discordant helix stabilization for prevention of amyloid formation

US7700751B2
(en)

2000-12-06
2010-04-20
Janssen Alzheimer Immunotherapy
Humanized antibodies that recognize β-amyloid peptide

PE20020574A1
(en)

2000-12-06
2002-07-02
Wyeth Corp

HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA

WO2002088307A2
(en)

2001-04-30
2002-11-07
Eli Lilly And Company
Humanized antibodies

EP2165714B1
(en)

2001-04-30
2013-10-23
Eli Lilly And Company
Humanized antibodies recognizing the beta-amyloid peptide

AU2002345843A1
(en)

2001-06-22
2003-01-08
Panacea Pharmaceuticals, Inc.
Compositions and methods for preventing protein aggregation in neurodegenerative diseases

DK1944040T3
(en)

2001-08-17
2012-10-29
Univ Washington

Method of analysis for Alzheimer’s disease

US7479482B2
(en)

2001-11-21
2009-01-20
New York University
Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto

US20030219459A1
(en)

2002-01-18
2003-11-27
Cytos Biotechnology Ag
Prion protein carrier-conjugates

AR038568A1
(en)

2002-02-20
2005-01-19
Hoffmann La Roche

ANTI-A BETA ANTIBODIES AND ITS USE

MY139983A
(en)

2002-03-12
2009-11-30
Janssen Alzheimer Immunotherap
Humanized antibodies that recognize beta amyloid peptide

US20050164361A1
(en)

2002-03-22
2005-07-28
David Lynn
Self-assembling-peptide-based structures and processes for controlling the self-assembly of such structures

US20090280114A1
(en)

2002-04-12
2009-11-12
Ramot At Tel Aviv University Ltd.
Prevention of brain inflammation as a result of induced autoimmune response

WO2010011999A2
(en)

2008-07-25
2010-01-28
The Regents Of The University Of California
Methods and compositions for eliciting an amyloid-selective immune response

ATE468886T1
(en)

2003-02-10
2010-06-15
Applied Molecular Evolution

ABETA-BINDING MOLECULES

PE20050627A1
(en)

2003-05-30
2005-08-10
Wyeth Corp

HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE

US20070110750A1
(en)

2003-09-12
2007-05-17
The Regents Of The University Of California
Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence

US7927594B2
(en)

2004-07-30
2011-04-19
Rinat Neuroscience Corp.
Antibodies directed against amyloid-beta peptide

WO2006066089A1
(en)

2004-12-15
2006-06-22
Neuralab Limited
Humanized amyloid beta antibodies for use in improving cognition

PE20061152A1
(en)

2004-12-15
2006-10-13
Neuralab Ltd

HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE

GT200600031A
(en)

2005-01-28
2006-08-29

ANTI-BETA ANTIBODY FORMULATION

ES2259270B1
(en)

2005-03-09
2007-11-01
Consejo Superior De Investigaciones Cientificas

IN VITRO DIAGNOSTIC METHOD OF ALZHEIMER’S DISEASE BY A MONOCLONAL ANTIBODY.

MY148086A
(en)

2005-04-29
2013-02-28
Rinat Neuroscience Corp
Antibodies directed against amyloid-beta peptide and methods using same

SI1960428T1
(en)

2005-12-12
2011-10-28
Hoffmann La Roche
Antibodies against amyloid beta with glycosylation in the variable region

US8784810B2
(en)

2006-04-18
2014-07-22
Janssen Alzheimer Immunotherapy
Treatment of amyloidogenic diseases

WO2008011348A2
(en)

2006-07-14
2008-01-24
Ac Immune S.A.
Humanized antibody against amyloid beta

US8066999B2
(en)

2007-01-18
2011-11-29
Eli Lilly And Company
PEGylated Aβ fab

US8003097B2
(en)

2007-04-18
2011-08-23
Janssen Alzheimer Immunotherapy
Treatment of cerebral amyloid angiopathy

US8048420B2
(en)

2007-06-12
2011-11-01
Ac Immune S.A.
Monoclonal antibody

US8613923B2
(en)

2007-06-12
2013-12-24
Ac Immune S.A.
Monoclonal antibody

DK2182983T3
(en)

2007-07-27
2014-07-14
Janssen Alzheimer Immunotherap

TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES

SG10201505369QA
(en)

2007-10-05
2015-08-28
Genentech Inc
Use of anti-amyloid beta antibody in ocular diseases

JO3076B1
(en)

2007-10-17
2017-03-15
Janssen Alzheimer Immunotherap
Immunotherapy regimes dependent on apoe status

LT2310412T
(en)

2008-06-20
2018-07-10
Novartis Ag
Immunoglobulins with reduced aggregation

US9067981B1
(en)

2008-10-30
2015-06-30
Janssen Sciences Ireland Uc
Hybrid amyloid-beta antibodies

US10196700B2
(en)

2009-03-24
2019-02-05
University Of Chicago
Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes

JP5766178B2
(en)

2009-03-24
2015-08-19
ザ・ユニバーシティ・オブ・シカゴＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣｈｉｃａｇｏ

Slipchip apparatus and method

US9464319B2
(en)

2009-03-24
2016-10-11
California Institute Of Technology
Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes

US9447461B2
(en)

2009-03-24
2016-09-20
California Institute Of Technology
Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes

MX338775B
(en)

2009-06-04
2016-05-02
Novartis Ag
METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION.

US8107653B2
(en)

2009-06-25
2012-01-31
Jerry Leigh Of California, Inc.
Garment with built-in audio source wiring

MX341369B
(en)

2010-07-30
2016-08-17
Genentech Inc *
Safe and functional humanized anti beta-amyloid antibody.

US9926353B2
(en)

2011-07-19
2018-03-27
New York University
Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides

US8906382B2
(en)

2011-07-19
2014-12-09
New York University
Method for treating amyloid disease

US9822356B2
(en)

2012-04-20
2017-11-21
California Institute Of Technology
Fluidic devices and systems for sample preparation or autonomous analysis

US9808798B2
(en)

2012-04-20
2017-11-07
California Institute Of Technology
Fluidic devices for biospecimen preservation

US9803237B2
(en)

2012-04-24
2017-10-31
California Institute Of Technology
Slip-induced compartmentalization

KR20180020169A
(en)

2015-06-24
2018-02-27
에프. 호프만-라 로슈 아게

Anti-transferrin receptor antibody with adjusted affinity

PE20231655A1
(en)

2015-10-02
2023-10-17
Hoffmann La Roche

BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE

AR106189A1
(en)

2015-10-02
2017-12-20
Hoffmann La Roche

BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE

US11692027B2
(en)

2016-09-28
2023-07-04
Board Of Regents, The University Of Texas System
Antibody and protein therapeutic formulations and uses thereof

WO2021113464A1
(en)

2019-12-04
2021-06-10
Friedman Simon
Protein blocking assembly and methods of making and using

Family Cites Families (5)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4946778A
(en)

1987-09-21
1990-08-07
Genex Corporation
Single polypeptide chain binding molecules

NL9102009A
(en)

1991-11-29
1993-06-16
Stichting Katholieke Univ

PRODUCTION OF BIOACTIVE PEPTIDES WITH RECOMBINANT CELLS.

JPH07504561A
(en)

1991-12-20
1995-05-25
ノボ　ノルディスク　アクティーゼルスカブ

Method for the production of lipase

WO1994008012A1
(en)

1992-10-02
1994-04-14
Research Corporation Technologies, Inc.
Methods for increasing secretion of overexpressed proteins

GB9223816D0
(en)

1992-11-13
1993-01-06
Medical Res Council
Heat shock proteins and the treatment of tumours

1994

1994-12-16
US
US08/358,786
patent/US5688651A/en
not_active
Expired – Lifetime

1995

1995-12-13
AU
AU45975/96A
patent/AU4597596A/en
not_active
Abandoned

1995-12-13
WO
PCT/US1995/016092
patent/WO1996018900A1/en
active
Application Filing

1995-12-15
IL
IL116416A
patent/IL116416A/en
unknown

Also Published As

Publication number
Publication date

IL116416A
(en)

2007-06-17

IL116416A0
(en)

1996-03-31

US5688651A
(en)

1997-11-18

WO1996018900A1
(en)

1996-06-20

Contact information